Literature DB >> 22627142

Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice.

Robert E Featherstone1, Yuling Liang, John A Saunders, Valerie M Tatard-Leitman, Richard S Ehrlichman, Steven J Siegel.   

Abstract

Ketamine is an NMDA receptor antagonist with psychotomimetic, dissociative, amnestic and euphoric effects. When chronically abused, ketamine users display deficits in cognition and information processing, even following long-term abstinence from the drug. While animal studies have shown evidence of behavioral changes and cognitive deficits that mimic those seen in humans within the period immediately following subchronic ketamine, a few animal studies have assessed long-term changes following cessation of ketamine exposure. To this end, the present study assessed event related potentials (ERPs) and EEG oscillations in mice exposed to subchronic ketamine following a 6month period of abstinence from the drug. Ketamine-treated mice showed no change in P20, but did show marked reductions in amplitude of the later N40 and P80 components, consistent with previous studies of acute ketamine exposure. Additionally, ketamine-treated animals showed a significant reduction in stimulus evoked theta oscillations. To assess the functional significance of these changes, mice were also assessed on a series of behavioral and cognitive tests, including progressive ratio (motivation), extinction (behavioral flexibility) and win-shift radial maze (spatial memory). Subchronic ketamine produced marked disruptions in reversal learning and spatial memory. Analysis of brains from ketamine-treated mice failed to show evidence of neuronal degeneration as determined by NueN immunohistochemistry, but did show increased astrocyte proliferation and decreased expression of the glial specific glutamate transporter, GLT-1. These results strongly suggest: 1) that subchronic ketamine induces significant changes in brain function that long exceed exposure to the drug; 2) that ketamine exposure in mice induces lasting cognitive impairments closely resembling those observed in human ketamine abusers; 3) that ERP and EEG measures are highly sensitive to alterations in brain function associated with reduced cognitive function; and 4) that the brain changes induced by chronic ketamine treatment are suggestive of long-term adaptive or plastic, rather than degenerative, changes.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22627142     DOI: 10.1016/j.nbd.2012.05.003

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  34 in total

1.  Coupling of gene expression in medial prefrontal cortex and nucleus accumbens after neonatal ventral hippocampal lesions accompanies deficits in sensorimotor gating and auditory processing in rats.

Authors:  Neal R Swerdlow; Susan B Powell; Michelle R Breier; Samantha R Hines; Gregory A Light
Journal:  Neuropharmacology       Date:  2013-06-26       Impact factor: 5.250

2.  Morin Attenuates Neurochemical Changes and Increased Oxidative/Nitrergic Stress in Brains of Mice Exposed to Ketamine: Prevention and Reversal of Schizophrenia-Like Symptoms.

Authors:  Benneth Ben-Azu; Adegbuyi Oladele Aderibigbe; Aya-Ebi Okubo Eneni; Abayomi Mayowa Ajayi; Solomon Umukoro; Ezekiel O Iwalewa
Journal:  Neurochem Res       Date:  2018-06-28       Impact factor: 3.996

3.  Hydroxynorketamine Blocks N-Methyl-d-Aspartate Receptor Currents by Binding to Closed Receptors.

Authors:  Jamie A Abbott; Gabriela K Popescu
Journal:  Mol Pharmacol       Date:  2020-06-29       Impact factor: 4.436

4.  Parvalbumin Cell Ablation of NMDA-R1 Leads to Altered Phase, But Not Amplitude, of Gamma-Band Cross-Frequency Coupling.

Authors:  Russell G Port; Jeffrey I Berman; Song Liu; Robert E Featherstone; Timothy P L Roberts; Steven J Siegel
Journal:  Brain Connect       Date:  2019-03-15

5.  Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats.

Authors:  R Moaddel; M Sanghvi; A Ramamoorthy; K Jozwiak; N Singh; C Green; K O'Loughlin; M Torjman; I W Wainer
Journal:  J Pharm Biomed Anal       Date:  2016-03-14       Impact factor: 3.935

6.  Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.

Authors:  Samuel T Wilkinson; DaShaun Wright; Madonna K Fasula; Lisa Fenton; Matthew Griepp; Robert B Ostroff; Gerard Sanacora
Journal:  Psychother Psychosom       Date:  2017-05-11       Impact factor: 17.659

7.  Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits.

Authors:  Eddie N Billingslea; Valerie M Tatard-Leitman; Jaynie Anguiano; Catherine R Jutzeler; Jimmy Suh; John A Saunders; Susumu Morita; Robert E Featherstone; Pavel I Ortinski; Michael J Gandal; Robert Lin; Yuling Liang; Raquel E Gur; Gregory C Carlson; Chang-Gyu Hahn; Steven J Siegel
Journal:  Neuropsychopharmacology       Date:  2014-02-14       Impact factor: 7.853

8.  Juvenile exposure to ketamine causes delayed emergence of EEG abnormalities during adulthood in mice.

Authors:  R E Featherstone; L R Nagy; C G Hahn; S J Siegel
Journal:  Drug Alcohol Depend       Date:  2013-09-27       Impact factor: 4.492

9.  Oxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonism.

Authors:  Rosanna Sobota; Takuma Mihara; Alexandra Forrest; Robert E Featherstone; Steven J Siegel
Journal:  Behav Neurosci       Date:  2015-08       Impact factor: 1.912

10.  Reverse translation of clinical electrophysiological biomarkers in behaving rodents under acute and chronic NMDA receptor antagonism.

Authors:  Elyse M Sullivan; Patricia Timi; L Elliot Hong; Patricio O'Donnell
Journal:  Neuropsychopharmacology       Date:  2014-09-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.